Key result
Review outlines evidence-based strategies for portal vein thrombosis across anticoagulation, conservative, and invasive therapies.
Answers are grounded in this paper and cite their sources.
Portal vein thrombosis is an unusual thrombotic condition not frequently seen in the general population; however, it has a higher prevalence in special circumstances such as in liver cirrhosis and hepatic or pancreatic malignancy. It also can be associated with significant morbidity and mortality. In this review, we discuss the current data available to guide therapy in the setting of different associated co-morbidities, hypercoagulable states, and associated thrombosis of the remaining splanchnic circulation. We discuss indications for anticoagulation, including the choice of anticoagulants, as well as the role of conservative 'wait and watch' and invasive therapies, such as thrombolysis, thrombectomy, and transjugular intrahepatic portosystemic shunt.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2015) conducted a review in Portal vein thrombosis. Anticoagulation, thrombolysis, thrombectomy, and transjugular intrahepatic portosystemic shunt vs. Wait and watch was evaluated. This review discusses the current data available to guide therapy for portal vein thrombosis, including indications for anticoagulation, conservative management, and invasive therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: